Tea Consumption and Mortality After Acute Myocardial Infarction

Kenneth J. Mukamal, MD, MPH, MA; Malcolm Macleure, ScD; James E. Muller, MD; Jane B. Sherwood, RN; Murray A. Mittleman, MD, DrPH

Background—Some studies have suggested that tea consumption may be associated with lower mortality among individuals with cardiovascular disease, but the effects of tea consumption on mortality after acute myocardial infarction are unknown.

Methods and Results—As part of the Determinants of Myocardial Infarction Onset Study, we performed a prospective cohort study of 1900 patients hospitalized with a confirmed acute myocardial infarction between 1989 and 1994, with a median follow-up of 3.8 years. Trained interviewers assessed self-reported usual weekly caffeinated tea consumption during the year before infarction with a standardized questionnaire. We compared long-term mortality according to tea consumption using Cox proportional hazards regression. Of the 1900 patients, 1019 consumed no tea (nondrinkers), 615 consumed <14 cups per week (moderate tea drinkers), and 266 consumed 14 or more cups per week (heavy tea drinkers). Compared with nondrinkers, age- and sex-adjusted mortality was lower among moderate tea drinkers (hazard ratio, 0.69; 95% CI, 0.53 to 0.89) and heavy tea drinkers (hazard ratio, 0.61; 95% CI, 0.42 to 0.86). Additional adjustment for clinical and sociodemographic characteristics did not appreciably alter this association (hazard ratio, 0.72; 95% CI, 0.55 to 0.94 for moderate tea drinkers; hazard ratio, 0.56; 95% CI, 0.37 to 0.84 for heavy tea drinkers). The association of tea and mortality was similar for total and cardiovascular mortality.

Conclusions—Self-reported tea consumption in the year before acute myocardial infarction is associated with lower mortality after infarction. (Circulation. 2002;105:2476-2481.)

Key Words: mortality ■ myocardial infarction ■ nutrition

The effects of tea on health have been widely studied, in part because tea contains flavonoids and other antioxidant components. Flavonoids are a ubiquitous class of antioxidants found naturally in various foods derived from plants, especially black and green tea, and are hypothesized to prevent cardiovascular disease. For example, by inhibiting the oxidation of low-density lipoprotein cholesterol, flavonoids could lower its atherogenicity. Epidemiological evidence linking tea or flavonoid consumption with coronary heart disease or total mortality among healthy adults is conflicting, but tea consumption may have its strongest effect among patients with cardiovascular disease. For example, one study of men with prevalent cardiovascular disease found that flavonoid intake was associated with 37% lower coronary mortality, but this finding had limited precision and was not statistically significant.
myocardial infarction. Trained research interviewers identified eligible patients by reviewing coronary care unit admission logs and patient charts. For inclusion, patients were required to have a creatine kinase level above the upper limit of normal for each center, positive MB isoenzymes, an identifiable onset of symptoms of infarction, and the ability to complete a structured interview. For these analyses, we excluded patients with missing information about usual tea consumption (n = 35), leaving 1900 eligible patients. The institutional review board of each center approved this protocol, and each patient gave informed consent.

Interviewers used a structured data abstraction and questionnaire form. Participants were asked their usual frequency of consumption of caffeinated tea over the last year. Based on the distribution of tea consumption within the Onset Study population, we categorized usual tea consumption as none, <14 cups per week (moderate use), or ≥14 cups per week (heavy use). We did not determine the consumption of decaffeinated tea.

Other information collected from each interview and chart review included demographics, medical history, and medication use (both prescription and nonprescription). During the chart review, interviewers recorded complications of congestive heart failure and ventricular tachycardia based on diagnoses recorded in the medical record. Interviewers also recorded all creatine kinase values available at the time of the interview.

We defined present aspirin use as the reported use of any aspirin or aspirin-containing product in the 4 days before the index myocardial infarction, based on previous Onset Study analyses and the duration of its physiological effect. We defined initial hypotension as presenting systolic blood pressure <90 mm Hg. We used 1990 United States census data to derive median household income from United States Postal Service zip codes. We derived body mass index as the weight (in kilograms) divided by the square of the height (in meters). We defined noncardiac comorbidity as a previous history of stroke, respiratory disease, renal disease, or cancer. We determined weekly non-tea caffeine consumption from reported caffeinated tea consumption of decaffeinated tea.

We searched the National Death Index for deaths of Onset Study subjects through December 31, 1995 and requested death certificates from state offices of vital records for all probable matches, using a previously validated algorithm. Three physicians blinded to each participant’s tea consumption independently verified the determination of each death. Two physicians categorized each death as attributable to cardiovascular or noncardiovascular causes. Disagreements among raters were resolved by discussion.

**Statistical Analysis**

We analyzed continuous and binary variables using ANOVA and Fisher’s exact tests, respectively. We used Cox proportional-hazards models to examine the association of tea intake with survival after adjustment for potentially confounding factors. The covariates we included were age, sex, previous myocardial infarction, diabetes mellitus, hypertension, noncardiac comorbidity, medication use (aspirin, β-adrenergic antagonists, calcium-channel blockers, digoxin, diuretics, lipid-lowering agents, and ACE inhibitors), present smoking, previous smoking, body mass index, use of thrombolytic therapy, usual frequency of exertion (in 3 categories), usual alcohol consumption (in 3 categories), household income (in quartiles), educational attainment (in 3 categories), and complications of congestive heart failure or ventricular tachycardia during hospitalization. As previously described, we also included an interaction term between age and sex in all models. Models that incorporated covariates on the basis of stepwise selection procedures yielded identical results and are not shown here. We assigned indicator variables for subjects with missing information on education (n = 58) and income (n = 60). For all other covariates, subjects with missing information were deleted from multivariate models (n = 77). Models that assigned these subjects mean levels of continuous covariates and modal levels of binary covariates yielded nearly identical results and are not shown here. We tested the assumption of proportional hazards using time-varying covariates and found no violations. For all analyses, we present 95% CIs and probability values from 2-sided statistical tests using SAS software (Release 8; SAS Institute).

To assess the robustness of our findings, we also tested tea consumption using propensity analysis. Each patient’s score represents that individual’s probability of consuming a given amount of tea, relative to abstention from tea. To calculate propensity scores, we used logistic regression models in which the dependent variable was moderate to heavy tea consumption (compared with abstention), using all covariates noted above (except thrombolytic therapy and complications during hospitalization), as well as usual coffee consumption (in 3 categories), multivitamin supplement use, previous angina, previous congestive heart failure, quadratic terms for age and body mass index, and interactions of sex with age and race. We then used the actual propensity score in Cox models along with age, sex, and measures of infarct treatment and severity (receipt of thrombolytic therapy, complications during hospitalization, peak creatine kinase level, and initial hypotension). We tested moderate and heavy tea consumption in separate propensity models.

**Results**

The characteristics of the Onset Study participants have been previously reported. Table 1 shows patient characteristics according to usual tea consumption. Median tea consumption was 2 cups weekly among patients consuming <14 cups weekly (moderate tea drinkers) and 19 cups weekly among patients consuming ≥14 cups weekly (heavy tea drinkers). Heavy tea drinkers were more likely to be older and female and had lower mean body mass index, but they had a similar prevalence of hypertension and smoking and similar levels of education and household income. Ventricular tachycardia during hospitalization, abstention from alcohol, and a sedentary lifestyle were somewhat less frequent among intermediate tea drinkers but not heavy tea drinkers. Coffee and tea consumption were inversely correlated (Spearman rank correlation coefficient, −0.09; P < 0.001).

Of the 1900 eligible patients, 313 (16%) died during a median (and mean) follow-up of 3.8 years. Approximately 75% of the deaths were from cardiovascular causes. Table 2 shows the relation of tea consumption to total mortality. In age- and sex-adjusted analyses, we found a graded inverse relationship between tea consumption and mortality. Additional control for sociodemographic and clinical characteristics attenuated the inverse association among intermediate tea drinkers but actually strengthened it among heavier tea drinkers. Table 2 also shows that tea consumption was inversely associated with cardiovascular mortality, with a pattern similar to that for overall mortality, as expected from the predominance of cardiovascular deaths.

To evaluate the robustness of our findings, we performed several sensitivity analyses. When we controlled for coffee consumption in addition to the covariates in the full model, the hazard ratios were 0.77 (95% CI, 0.59 to 1.01) among intermediate tea drinkers and 0.60 (95% CI, 0.40 to 0.90) among heavier tea drinkers. Propensity analysis produced similar estimates, with hazard ratios for total mortality of 0.76 (95% CI, 0.58 to 0.99) for moderate tea drinkers and 0.62 (95% CI, 0.41 to 0.93) for heavy tea drinkers. Exclusion of the 44 participants who died within 30 days of hospitalization did not affect our findings (data not shown). In selected patient subgroups, we found generally similar inverse associations of tea consumption with mortality regardless of age,
<table>
<thead>
<tr>
<th>Usual Weekly Tea Consumption</th>
<th>None</th>
<th>&lt;14 Cups</th>
<th>≥14 Cups</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>1019</td>
<td>615</td>
<td>266</td>
<td></td>
</tr>
<tr>
<td>Age, y†</td>
<td>61±12</td>
<td>61±13</td>
<td>63±13</td>
<td>0.06</td>
</tr>
<tr>
<td>Female, %</td>
<td>29</td>
<td>31</td>
<td>41</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>White, %</td>
<td>92</td>
<td>89</td>
<td>90</td>
<td>0.11</td>
</tr>
<tr>
<td>BMI, kg/m²†</td>
<td>27.5±5.3</td>
<td>27.2±5.0</td>
<td>26.4±5.0</td>
<td>0.02</td>
</tr>
<tr>
<td>Present smoker, %</td>
<td>35</td>
<td>32</td>
<td>32</td>
<td>0.42</td>
</tr>
<tr>
<td>Former smoker, %</td>
<td>43</td>
<td>40</td>
<td>39</td>
<td>0.29</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>44</td>
<td>44</td>
<td>45</td>
<td>0.87</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>22</td>
<td>20</td>
<td>17</td>
<td>0.14</td>
</tr>
<tr>
<td>Previous myocardial infarction, %</td>
<td>30</td>
<td>27</td>
<td>25</td>
<td>0.31</td>
</tr>
<tr>
<td>Noncardiac comorbidity, %‡</td>
<td>13</td>
<td>17</td>
<td>17</td>
<td>0.08</td>
</tr>
<tr>
<td>Regular use of</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin, %</td>
<td>33</td>
<td>33</td>
<td>35</td>
<td>0.78</td>
</tr>
<tr>
<td>β-blockers, %</td>
<td>22</td>
<td>18</td>
<td>19</td>
<td>0.16</td>
</tr>
<tr>
<td>Ca²⁺-blockers, %§</td>
<td>26</td>
<td>22</td>
<td>23</td>
<td>0.12</td>
</tr>
<tr>
<td>ACE inhibitors, %</td>
<td>12</td>
<td>13</td>
<td>9</td>
<td>0.20</td>
</tr>
<tr>
<td>Digoxin, %</td>
<td>8</td>
<td>7</td>
<td>8</td>
<td>0.52</td>
</tr>
<tr>
<td>Hypolipidemics, %</td>
<td>8</td>
<td>8</td>
<td>6</td>
<td>0.79</td>
</tr>
<tr>
<td>Diuretics, %</td>
<td>20</td>
<td>19</td>
<td>21</td>
<td>0.77</td>
</tr>
<tr>
<td>Thrombolytic use, %</td>
<td>34</td>
<td>39</td>
<td>38</td>
<td>0.12</td>
</tr>
<tr>
<td>Complications during admission, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHF¶</td>
<td>15</td>
<td>14</td>
<td>15</td>
<td>0.81</td>
</tr>
<tr>
<td>VT¶</td>
<td>15</td>
<td>9</td>
<td>11</td>
<td>0.002</td>
</tr>
<tr>
<td>Income, $†#</td>
<td>38 322±13 169</td>
<td>38 822±13 282</td>
<td>37 699±12 671</td>
<td>0.50</td>
</tr>
<tr>
<td>Exertion ≥6 MET (episodes/week), %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td>83</td>
<td>78</td>
<td>83</td>
<td>0.03</td>
</tr>
<tr>
<td>1–4</td>
<td>9</td>
<td>13</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>≥5</td>
<td>8</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Education, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than high school</td>
<td>25</td>
<td>22</td>
<td>26</td>
<td>0.35</td>
</tr>
<tr>
<td>High school</td>
<td>40</td>
<td>42</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Some college</td>
<td>35</td>
<td>35</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Alcohol intake (servings/week), %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>51</td>
<td>41</td>
<td>47</td>
<td>0.002</td>
</tr>
<tr>
<td>&lt;7</td>
<td>33</td>
<td>42</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>≥7</td>
<td>16</td>
<td>17</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Caffeinated coffee intake (cups/week), †</td>
<td>18±27</td>
<td>16±19</td>
<td>12±28</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>None, %</td>
<td>27</td>
<td>18</td>
<td>40</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>≤14, %</td>
<td>39</td>
<td>51</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>&gt;14, %</td>
<td>34</td>
<td>31</td>
<td>23</td>
<td></td>
</tr>
</tbody>
</table>

*P values for binary and continuous variables derive from exact tests and ANOVA, respectively.  
†Mean values with SD are shown for continuous variables.  
‡Noncardiac comorbidity included a previous history of stroke, cancer, renal disease, or respiratory disease.  
§Ca²⁺-blockers indicates calcium-channel blockers.  
¶CHF indicates congestive heart failure during the index hospitalization.  
¶VT indicates ventricular tachycardia during the index hospitalization.  
#Household income was derived from zip codes according to 1990 United States Census Bureau data.
TABLE 2. Hazard Ratios for All-Cause and Cardiovascular Mortality After Acute Myocardial Infarction According to Usual Weekly Tea Consumption Among Onset Study Participants

<table>
<thead>
<tr>
<th>Usual Weekly Tea Consumption</th>
<th>None</th>
<th>&lt;14 Cups</th>
<th>≥14 Cups</th>
<th>P (trend)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>1019</td>
<td>615</td>
<td>266</td>
<td></td>
</tr>
<tr>
<td>Deaths (%)</td>
<td>191 (19)</td>
<td>86 (14)</td>
<td>37 (14)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular deaths (%)</td>
<td>141 (14)</td>
<td>67 (11)</td>
<td>26 (10)</td>
<td></td>
</tr>
<tr>
<td>Person-years</td>
<td>3747</td>
<td>2278</td>
<td>981</td>
<td></td>
</tr>
<tr>
<td>Age- and sex-adjusted (95% CI)</td>
<td>1.00</td>
<td>0.69 (0.53–0.89)</td>
<td>0.61 (0.42–0.86)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Full model* (95% CI)</td>
<td>1.00</td>
<td>0.72 (0.55–0.94)</td>
<td>0.56 (0.37–0.84)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CV mortality† (95% CI)</td>
<td>1.00</td>
<td>0.79 (0.58–1.08)</td>
<td>0.54 (0.33–0.87)</td>
<td>0.005</td>
</tr>
</tbody>
</table>

*The full model adjusted for age, sex, previous myocardial infarction, noncardiac comorbidity, hypertension, diabetes, body mass index, present smoking, former smoking, educational attainment, race, household income, usual frequency of exertion, usual alcohol consumption, use of thrombolytic therapy, use of cardiac medications (aspirin, β-blockers, calcium-channel blockers, digoxin, diuretics, lipid-lowering agents, or ACE inhibitors), and congestive heart failure or ventricular tachycardia during hospitalization.

†These models show hazard ratios for death from cardiovascular causes, adjusted for the same covariates as the full model.

sex, smoking status, obesity, hypertension, diabetes, or previous infarction (data not shown).

In another stratified analysis, we found an interaction of borderline significance (P=0.08) between alcohol consumption and tea consumption. Among 1061 patients who consumed <1 alcoholic drink per month, the hazard ratios for total mortality were 0.63 (95% CI, 0.45 to 0.88) for moderate tea drinkers and 0.44 (95% CI, 0.27 to 0.73) for heavy tea drinkers after adjustment for all other covariates other than alcohol use. Among 787 patients who drank alcohol at least monthly (median, 5 servings per week), the corresponding hazard ratios were 0.83 (95% CI, 0.52 to 1.32) and 0.79 (95% CI, 0.41 to 1.53).

To evaluate whether caffeine intake per se was responsible for the inverse association of tea consumption and mortality, we assessed non-tea caffeine intake and mortality in similar fashion. Non-tea caffeine intake was not associated with mortality (adjusted hazard ratio per 1000 mg of caffeine intake per week, 1.01; 95% CI, 0.97 to 1.06).

Discussion

In this multicenter, prospective study of early survivors of acute myocardial infarction, we found that self-reported tea consumption during the year before infarction was associated with lower subsequent mortality after infarction. This association was graded, unchanged by adjustment for sociodemographic and clinical characteristics after controlling for age and sex, and extended to both total and cardiovascular mortality.

We know of no previous studies that have specifically examined the effect of tea consumption after acute myocardial infarction. In a secondary analysis of the Health Professionals Follow-Up Study, Rimm et al49 found that higher flavonoid intake was associated with a lower risk of coronary mortality only among men with prevalent cardiovascular disease. Although only 105 men died during follow-up and the findings did not reach statistical significance, their results agree well with ours (relative risk, 0.63; 95% CI, 0.33 to 1.20). Klatsky et al11 found a weak but statistically significant effect of tea consumption on mortality only among individuals with baseline morbidity (relative risk per cup per day, 0.98; P=0.04), although this group included subjects with a diverse set of diagnoses. The Zutphen Elderly Study reported that a history of previous myocardial infarction did not statistically significantly modify the inverse association of flavonoid consumption with coronary mortality among men (P=0.58).7 However, only 112 men had sustained a previous infarction, of whom only 23 died, and the authors did not report the effect of flavonoid consumption in this small subgroup. All of these studies were limited to prevalent cases of cardiovascular disease, raising the possibility of survivorship bias.

Several possible mechanisms could explain an association between tea consumption and survival among patients with acute myocardial infarction. A recent randomized trial found that acute and chronic black tea consumption improved endothelial function in patients with coronary heart disease in an additive fashion.13 This provides a suggestive mechanism for a beneficial impact of tea intake on survivors of acute myocardial infarction, given the adverse prognosis associated with coronary endothelial dysfunction in patients with coronary heart disease.21 Flavonoids also inhibit LDL oxidation, perhaps by reducing macrophage superoxide production.2 Oxidized LDL may promote atheroma formation by increasing macrophage uptake,23 monocyte recruitment,23 and direct endothelial cell damage,24 and antioxidant use may prevent myocardial infarction, at least in some patients.25

Another hypothesized mechanism for a beneficial effect of tea on cardiovascular disease is an antithrombotic effect of flavonoids.26 Flavonoids inhibit platelet aggregation in vitro, perhaps via suppression of phosphodiesterase or cyclooxygenase activity,27 although whether this activity occurs in
vivo remains unclear. Because alcohol consumption also has antithrombotic activity, our finding that tea consumption seems most protective among alcohol abstainers supports this as a possible mechanism.

Whether the observed association between tea consumption and postinfarction survival reflects these physiological effects of tea or confounding by other factors associated with tea intake can only be answered in a large-scale, long-term randomized trial, although such a trial is unlikely to be performed in the near future.

We asked participants to report their usual tea consumption over the year before the infarction that resulted in their hospitalization. By measuring these variables prospectively, we minimized the possibility of differential misclassification during the follow-up period. For example, if sicker patients tend to give up tea consumption more often than healthier patients do after their infarctions, studies that assess postinfarction tea consumption may be biased in favor of tea consumption. The design of our study argues against that possibility. Interestingly, Cleophas et al found that tea consumption was essentially identical when considered 1 year before, during, or 1 year after an acute myocardial infarction. The inception cohort design of our study also minimizes the possibility that tea has different associations with intermediate- and long-term mortality after acute myocardial infarction, causing a survivorship bias.

Study Limitations
In this study, we asked patients to report their usual consumption of caffeinated tea, which includes black and green teas, and we cannot determine whether black tea differs from green tea in this study. We also may have misclassified patients who predominately drank decaffeinated tea as nondrinkers, although caffeinated black tea represents the bulk of tea consumed in the United States during the years of this study. Although we relied on self-reported tea intake, this method has proven valid among both women and men.

As with any observational study, the associations we observed could be accounted for, at least in part, by differences between tea drinkers and nondrinkers. For example, we did not have detailed dietary information available for these patients, and we cannot exclude the possibility that dietary differences account for some of the association between tea and survival. In this regard, results from the Zutphen Elderly Study are instructive; controlling for age and diet in that study than previous ones that relied on patients with prevalent cases of cardiovascular disease.

In summary, we found that tea consumption is associated with greater survival after acute myocardial infarction among Onset Study participants. This finding was consistent for total and cardiovascular mortality and did not change with additional adjustment after we controlled for age and sex. Although our findings support the hypothesis that tea consumption may improve survival among patients after acute myocardial infarction, confirmation of this relation from other observational studies or, better yet, controlled clinical trials is needed.

Acknowledgments
This study was supported by grants R01HL41016 from the National Heart, Lung, and Blood Institute, Bethesda, Md (for the Determinants of Myocardial Infarction Onset Study), K23AA00299 from the National Institute on Alcohol Abuse and Alcoholism, Bethesda, Md, and 9630115N from the American Heart Association, Dallas, Tex. We are grateful to Mylan Cohen, MD, MPH, for verifying death certificates, Alexander Georgakis, MA, MBA, for determining household income, and Kate Dwyer for administrative assistance.

References
10. Woodward M, Tunstall-Pedoe H. Coffee and tea consumption in the Scottish Heart Health Study follow up: conflicting relations with coronary
risk factors, coronary disease and all cause mortality. J Epidemiol Com-
Ann Epidemiol. 1993;375–381.
consumption reverses endothelial dysfunction in patients with coronary 
mortality following acute myocardial infarction. JAMA. 2001;285: 
15. Mukamal KJ, Mittleman MA, Mac lure M, et al. Recent aspirin use is 
associated with smaller myocardial infarct size and lower likelihood of 
17. Willett WC, Stampfer MJ, Manson JE, et al. Coffee consumption and 
coronary heart disease in women: a ten-year follow-up. JAMA. 1996;275: 
458–462.
Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994;140: 
1016–1019.
differences in survival after hospitalization for acute myocardial 
20. D’Agostino RB Jr. Propensity score methods for bias reduction in the 
comparison of a treatment to a non-randomized control group. Stat Med. 
21. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary 
vasodilator dysfunction on adverse long-term outcome of coronary heart 
22. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degra-
dation of biologically modified low density lipoproteins. Arteriosclerosis. 
density lipoproteins: a potential role in recruitment and retention of 
monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 
1987;84:2995–2998.
24. Hessler JR, Morel DW, Lewis LJ, et al. Lipoprotein oxidation and 
trial of vitamin E in patients with coronary disease: Cambridge Heart 
trans-resveratrol and quercetin block human platelet aggregation and 
eicosanoid synthesis: implications for protection against coronary heart 
27. Landonfi R, Mower RL, Steiner M. Modification of platelet function and 
arachidonic acid metabolism by bioflavonoids: structure-activity 
consumption on platelet aggregation in patients with coronary artery 
29. Renaud SC, Beswick AD, Fehily AM, et al. Alcohol and platelet aggre-
gation: the Caerphilly Prospective Heart Disease Study. Am J Clin Nutr. 
30. Cleophas TJM, Tuinenberg E, van der Meulen J, et al. Wine consump-
tion and other dietary variables in males under 60 before and after acute 
questionnaire: the effects of week-to-week variation in food consumption. 
32. Grobbee DE, Rimm EB, Giovannucci E, et al. Coffee, caffeine, and 
Tea Consumption and Mortality After Acute Myocardial Infarction
Kenneth J. Mukamal, Malcolm Maclure, James E. Muller, Jane B. Sherwood and Murray A. Mittleman

_Circulation_. 2002;105:2476-2481; originally published online May 6, 2002;
doi: 10.1161/01.CIR.000017201.88994.F7

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/105/21/2476

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/